Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and Etanercept in Myelodysplastic Syndromes
NCT00118287Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Apr 2005
- Primary completion
- Oct 2008
- Modality
- Small Molecules, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of azacitidine and etanercept in myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Started Apr 2005; status: completed.
02
Drugs
azacitidineetanercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00118287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00118287.